Tris Pharma’s opioid alternative has scored a third win in a trio of clinical trials, providing the biotech with the data ...

Under President Donald Trump’s administration, the Department of Government Efficiency (DOGE) has reportedly terminated ...

Denali Therapeutics’ amyotrophic lateral sclerosis (ALS) drug has racked up another clinical miss this year, leaving the ...

One of Merck KGaA’s leading immunology assets has flunked a phase 2 lupus trial. | One of Merck KGaA’s leading immunology ...

Sitting before senators at his confirmation hearing to become commissioner of the FDA, Johns Hopkins surgeon and author ...

Evidation has promoted its president and chief operating officer, Leslie Oley Wilberforce, to be its next CEO, as the ...

Amgen’s most advanced obesity asset MariTide is entering Maritime—that is, a phase 3 program that includes two freshly ...

But when it came to the secondary endpoint of interim overall survival (OS), the ITM-11 cohort reached 63.4 months while the ...

A federal judge has blocked the Trump administration’s effort to slash National Institutes of Health (NIH) grant payments. | ...

Jazz Pharmaceuticals has drummed up a deal in double time, agreeing to buy Chimerix for $935 million just days after its CEO ...

Bristol Myers Squibb is levering Fulcrum Therapeutics out of its life. | Bristol Myers Squibb is levering Fulcrum ...

President Donald Trump’s pick to lead the National Institutes of Health (NIH), Jayanta Bhattacharya, M.D., Ph.D., said ...